We hypothesize that the overexpression of MMP14 might have certain advantages over the expression of secreted heparanase or the systemic application of lysyl oxidase inhibitors, as MMP14 is a membrane-anchored protein lowering the risk of structural changes outside of the tumor tissue. The gene discussed is LOX; the disease is neoplasm.